Fulltext

Recombinant human Erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells

Shujaa Edin HY 1 , Al-Haj NA 2 , Rasedee A 3 , Banu Alitheen N 4 , Abdul Kadir A 3 , Wun How C 5 Show all authors , Sulaiman Rahman H 6 , Al-Shwyeh HA 7

Affiliations 

  • 1 Institute of Bioscience, Universiti Putra Malaysia,Malaysia
  • 2 Faculty of Medicine and Health Sciences, Sana'a University, Yemen
  • 3 Faculty of Veterinary Medicine, Universiti Putra Malaysia, Malaysia
  • 4 Faculty of Biotechnology and Biomolecular Sciences, University Putra Malaysia, Malaysia
  • 5 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia
  • 6 College of Medicine, University of Sulaimani, Kurdistan Region, Iraq
  • 7 Department of Biology, College of Science, Imam Abdulrahman Bin Faisal University (IAU), Dammam 31441-1982, Saudi Arabia
Saudi J Biol Sci, 2021 Sep;28(9):5214-5220.
PMID: 34466099 DOI: 10.1016/j.sjbs.2021.05.043

Abstract

Erythropoietin (EPO) is widely used to treat anemia in patients undergoing chemotherapy for cancers. The main objective of this study was to investigate the effect of rHuEPO on the response of spheroid breast cancer, MCF-7, cells to tamoxifen treatment. The MCF-7 spheroids were treated with 10 mg/mL tamoxifen in combination with either 0, 10, 100 or 200 IU/mL rHuEPO for 24, 48 or 72 h. The viability of the MCF-7 cells was determined using the annexin-V, cell cycle, caspases activation and acridine orange/propidium iodide staining. rHuEPO-tamoxifen combination significantly (p greater than 0.05) increased the number of spheroid MCF-7 cells entering early apoptotic phase after 12 h and late apoptotic phase after 24 h of treatment; primarily the result of the antiproliferative effect tamoxifen. Tamoxifen alone significantly (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications